Labiotech.eu

Johnson & Johnson’s pipeline strategy: What does 2026 have in store for the big pharma?

Discover J&J’s pipeline strategy for 2026 as it it projects that its sales for the year will be between $100 billion and $101 ...
Des Moines Register

Peek Healthcare Technologies, Inc. (‘Peek’) Launches Direct-to-Employer and Direct-to-Patient Pricing for IMULDOSA(R) (ustekinumab-srlf) (Stelara(R) Biosimilar)

IMULDOSA is a biosimilar to Stelara, a biologic therapy widely prescribed for autoimmune conditions such as Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis. By removing hidden ...

Johnson & Johnson Projects Strong Growth Beyond STELARA

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.
Drug Store News

Hikma launches Stelara biosimilar

Ustekinumab had a market value of approximately $17.1 billion for the 12 months ending December 2024, per IQVIA. Hikma is acquiring Insys' unit dose nasal and sublingual spray manufacturing equipment, ...